Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Gross Profit (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Gross Profit for 3 consecutive years, with $58.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 15.57% to $58.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $90.3 million, a 27.53% increase, with the full-year FY2025 number at $90.3 million, up 27.53% from a year prior.
  • Gross Profit was $58.5 million for Q4 2025 at Iovance Biotherapeutics, up from $29.0 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $58.5 million in Q4 2025 to a low of -$6.5 million in Q1 2024.
  • A 3-year average of $16.3 million and a median of $4.6 million in 2023 define the central range for Gross Profit.
  • Biggest YoY gain for Gross Profit was 1354.96% in 2025; the steepest drop was 7.18% in 2025.
  • Iovance Biotherapeutics' Gross Profit stood at $5.8 million in 2023, then skyrocketed by 766.47% to $50.6 million in 2024, then grew by 15.57% to $58.5 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Gross Profit are $58.5 million (Q4 2025), $29.0 million (Q3 2025), and $3.3 million (Q2 2025).